Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

Glucagon-like peptide-1 (GLP-1) receptor analogs are drugs that mimic fullness hormone GLP-1 and have been shown to reduce appetite, slow digestion, help stabilize blood sugar levels and impact ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

Hims&Hers Health (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year guidance, driven by strong subscriber growth and improving profitability.

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic ...

With Novo Nordisk’s patent on semaglutide set to expire in India, Dr Reddy’s is among the forerunners trying to bring the ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

Thirteen state Medicaid programs cover GLP-1 drugs like Wegovy or Zepbound for weight loss, though many are considering ...

Welcome to the healthier, happier world of 2030. Heart attacks and strokes are down 20%. A drop in food consumption has left ...